Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Standard Medicines
Drugs
Locations
Clinical Specialty
141-160 of 1,782 trials

High-Grade Glioma: Abemaciclib with Temozolomide

We are studying whether adding abemaciclib to temozolomide helps children and young adults with newly diagnosed high-grade glioma after radiotherapy. This trial compares the combination treatment to temozolomide alone.

GliomaEfficacy phase (II)>20 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteOncologyPediatrics

Pramipexole for Anhedonic Depression

We are studying the long-term effects of adding pramipexole to treatment for people with anhedonic depression. The goal is to see how well it works and how well patients tolerate it.

Depression>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemotePsychiatry

AR Positive Triple-Negative Breast Cancer: Bicalutamide and Abemaciclib Study

We are studying a combination of bicalutamide and abemaciclib for patients with AR positive triple-negative breast cancer. The goal is to see if this treatment helps control the disease and to evaluate its safety.

Locally Advanced Unresectable or Metastatic Androgen Receptor Positive Triple Negative Breast Cancer>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementOncology

Hydroceles and Spermatoceles: Comparing Sclerotherapy Treatments

We are studying two methods of sclerotherapy to see which one better reduces symptoms and requires fewer follow-up treatments. This trial also looks at pain levels during the procedure with and without local anesthesia.

SpermatoceleHydrocele>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesUrology

Recurrent Prostate Cancer: SpectraCure P18 System Study

We are evaluating a new treatment system using lasers and a drug for men with recurrent prostate cancer. The study aims to ensure safety and effectiveness in targeting and eliminating cancer cells.

Recurrent Prostate CancerSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesOncology

Lupus in Children: Anifrolumab Study

We are studying the safety and effectiveness of anifrolumab in children and teens with moderate to severe lupus. This trial aims to find the right dose and see how well it works compared to a placebo.

Systemic Lupus Erythematosus>2 yearsConfirmation phase (III)>20 visitsPost-Trial Drug AccessStandard MedicinesPartially RemotePediatricsRheumatology

Patient-Controlled Sedation for Perineal Laceration Repair

We are studying if adding propofol sedation improves comfort for women during the repair of grade I and II obstetric perineal lacerations. This trial aims to see if it reduces pain and discomfort compared to standard care.

Obstetric Perineal Lacerations6-12 monthsConfirmation phase (III)No PlaceboStandard MedicinesGynecology and ObstetricsOtolaryngology

Alpha-Thalassemia: Luspatercept Treatment Study

We are investigating whether Luspatercept can improve anemia in adults and adolescents with Alpha-thalassemia. The study will also assess the safety of this treatment in younger participants.

Alpha ThalassemiaEfficacy phase (II)Post-Trial Drug AccessStandard MedicinesPartially RemoteHematology

Tuberous Sclerosis Complex: mTOR Inhibitor Treatment in Infants

We are studying the effects of a new treatment on brain development in infants with tuberous sclerosis complex. This trial aims to see if the treatment improves cognitive and behavioral outcomes compared to standard care.

Tuberous Sclerosis>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteNeurologyPediatrics

Breast Cancer Treatment: Tucatinib and Capecitabine

We are studying a combination of tucatinib, capecitabine, and trastuzumab for patients with HER2-positive breast cancer that has spread to the meninges. The goal is to see if this treatment improves survival and quality of life.

HER2-Amplified Metastatic Breast Cancer with Leptomeningeal Metastases>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Triple Negative Metastatic Breast Cancer: Sacituzumab Govitecan Study

We are investigating the safety and effectiveness of a new treatment for patients with triple negative metastatic breast cancer whose disease has worsened after prior therapies. This study will help us learn more about how well this treatment works and its safety profile.

Triple Negative Metastatic Breast Cancer>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesOncology

Prostate Cancer: New Treatment Approach with Hormone Therapy

We are studying whether adding short-term hormone therapy to a targeted treatment helps men with recurrent prostate cancer and a limited number of metastases live longer and improve their quality of life.

Oligorecurrent Hormone-Sensitive Prostate Cancer>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesOncologyUrology

CAR-T-Cell Treatment for High-Risk Mantle Cell Lymphoma

We are exploring a new CAR-T-cell therapy for patients with untreated high-risk Mantle Cell Lymphoma. The study compares this new approach to the standard treatment to see which is more effective and safer.

Mantle Cell Lymphoma>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesHematologyOncology

Prostate Cancer: 177Lu-PSMA-617 Treatment Study

We are evaluating whether adding 177Lu-PSMA-617 to standard treatment helps men with metastatic hormone-sensitive prostate cancer who are not responding well to current therapies. The goal is to see if this combination improves survival and disease control.

Hormone-sensitive Metastatic Prostate Cancer3-6 monthsConfirmation phase (III)16-20 visitsNo PlaceboStandard MedicinesPartially RemoteOncologyUrology

Advanced Colorectal Cancer: Cetuximab with Encorafenib and Binimetinib

We are studying a combination of three medications for patients with BRAF V600E mutated advanced colorectal cancer. The goal is to see if this treatment can help make surgery possible and improve overall health outcomes.

Colorectal Cancer>2 yearsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesInternal MedicineOncology

Thromboprophylaxis for Advanced Germ Cell Tumors

We are studying a preventive treatment for patients with advanced germ cell tumors undergoing chemotherapy to see if it can help reduce the risk of blood clots. The trial also looks at the safety and cost-effectiveness of this treatment.

Testicular Germ Cell Tumor3-6 monthsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesHematologyOncology

Cutaneous T-Cell Lymphoma: Mogamulizumab and Skin Radiation Therapy

We are studying a new treatment combining an antibody and skin radiation for patients with stage IB-IIB cutaneous T-cell lymphoma. The goal is to see if this approach improves survival and response rates compared to standard treatments.

Cutaneous T-cell LymphomaMycosis Fungoides and Sézary Syndrome>2 yearsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesOncology

Acute Myeloid Leukemia: Gilteritinib vs. Midostaurin

We are studying whether gilteritinib works better than midostaurin for patients with AML or MDS with a FLT3 mutation. This trial looks at treatment effectiveness and safety during chemotherapy and maintenance therapy.

Acute Myeloid Leukemia (AML)Myelodysplastic Syndrome with Excess Blasts 2 (MDS-EB2)1-2 yearsEfficacy phase (II)No PlaceboStandard MedicinesHematologyOncology

Beta-Thalassemia: Luspatercept for Children

We are studying a new treatment called luspatercept for children with beta-thalassemia to find a safe dose and evaluate its effects on blood health. This trial includes both transfusion-dependent and non-transfusion-dependent participants.

Beta Thalassemia>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementHematologyPediatrics

Atrial Fibrillation: Warfarin Study for Dialysis Patients

We are investigating the safety and effectiveness of warfarin in patients with atrial fibrillation who are on dialysis. This study aims to understand how this medication impacts their health.

Atrial FibrillationEnd-Stage Renal Disease>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesCardiologyNephrology